Select your language:

The Contrast Media Safety Committee of the European Society of Urogenital Radiology is proud to present the 10th version of its Contrast Agent Guidelines


We started in 1994 and we have on average updated the booklet every 2 to 3 years. Over the years, more than 200,000 copies of the booklet have been printed and it has been translated into many languages. Although the contrast agents in current use have been on the market for many years, minor changes occur in their adverse reaction pattern and new observations are reported.

The 10th version of the Guidelines includes updated sections on acute adverse reactions, gadolinium contrast agents and other gadolinium issues, post contrast acute kidney injury (PC-AKI) and myeloma and contrast media. The CMSC has decided to regularize its use of the terms 'contrast agent' and 'contrast medium' and there is a brief section on terminology a the start of the Guidelines.

We hope that you like the new version, that it is helpful in your practice and that it will benefit all our patients. Comments and questions are welcome at cmscmails(at)gmail.com

 

Contrast Media Safety Committee 

March 2018
Henrik S. Thomsen, Chairman

 

NOTE: CMSC guidelines are based on evidence in the literature whenever possible. Where there is insufficient published evidence, guidelines are based on clinical consensus within the Committee.

Some CMSC guidelines may differ from the Summary of Product Characteristics (SPC, label), and/or guidelines drawn up by national and other radiological bodies.

LEGAL NOTICE: The Committee and authors of the 10.0 contrast media guidelines claim no responsibility for the content of the translated versions of the guidelines.

 


QUICK GUIDE TO THE CMSC CONTRAST AGENT GUIDELINES, VERSION 10

 

Terminology: Contrast agents and contrast media

 

SECTION A: GENERAL ADVERSE REACTIONS

Includes material on:
• Acute adverse reactions to iodine- and gadolinium-based contrast agents.

• Management of acute adverse reactions to iodine- and gadolinium-based and ultrasound contrast agents.

• Late adverse reactions.

• Thyrotoxicosis.

• Nephrogenic systemic fibrosis (NSF).

 

SECTION B: RENAL ADVERSE REACTIONS (POST CONTRAST ACUTE KIDNEY INJURY, PC-AKI)

Includes material on:
• Measurement of renal function.

• Renal adverse reactions to iodine- and gadolinium-based contrast agents.

• Metformin.

 

SECTION C: MISCELLANEOUS

All other topics for which the Committee has prepared guidelines, including:

• Pediatric use of contrast agents.

• Contrast medium extravasation.

• Pregnancy and lactation.

• Ultrasound contrast agents.

• Barium contrast media.

• Off-label use of contrast agents.